Citius Oncology Inc CTOR

$0.61 +0.01 (2.40%)

Valuation

Market cap
53,882,000
Revenue TTM
$0
Net income TTM
$-24,760,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.50

Trading

Volume
134,800
Avg volume
97,518
Day's range
$0.57 – $0.65
Shares out
92,981,000
Stochastic %K
39%
Beta
3.39
Analysts
Strong Sell
Price target
$4.00

Price

Company profile

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Bio...

Show more

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
908 967 6677
Website
https://citiusonc.com/overview/default.aspx
Address
11 Commerce Drive, First Floor, Cranford, United States

Latest news

Stocktwits

CapitalTrades Oct 26, 8:46 PM
$CTOR
1 replies
KryptonKnight Oct 26, 7:16 PM
Keep a close watch on ticker ICMB 💎 ICMB sitting under a dollar when the real value is at $3.44, that's a 300%+ move from here. Huge opportunity here to bank. Make sure to be early on ICMB, before it takes off! $AMOD $CAST $CTOR ./;:)
0 replies
focafoca99 Oct 26, 6:04 PM
$CTOR communicates a 120% surge in LYMPHIR shipments to U.S. wholesalers in Q4 2026, with institutional demand rising.
0 replies
Dieseld28 Oct 26, 5:56 PM
$GCTK $CTOR
0 replies
Momentum_Scalper Oct 26, 5:47 PM
$CTOR Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
0 replies
TwongStocks Oct 26, 5:40 PM
$CTOR Preliminary Fiscal Fourth Quarter 2026 Highlights (unaudited) • 792 units purchased by U.S. wholesalers for the three months ended September 30, 2026, compared to 360 units for the three months ended June 30, 2026, an increase of 120%. https://citiusonc.com/news/news-details/2026/Citius-Oncology-Reports-Continued-Institutional-Demand-and-120-Growth-in-Shipments-of-LYMPHIR-Units-to-U-S--Wholesalers-During-the-Fiscal-Fourth-Quarter-of-2026/default.aspx Apr-Jun was $1.5M in revenue. Units sold to wholesalers from Jul-Sep increased from 360 to 792. So looking at over $3M-ish for last qtr. Final number depends on gross-to-net adjustments.
0 replies
TwongStocks Oct 23, 8:29 PM
$CTOR They got an extension through April 19, 2027 to regain compliance with the $1 rule. https://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390026112109/ea0309307-8k_citius.htm
0 replies
RME47pilot Oct 21, 7:43 PM
$CTOR Let's see 91.75 millions shares at this price, what maybe a 4:1 reverse split coming. Dilute it down so it takes two years to reach the rock bottom price of a quarter? This stock is junk, just like CTXR.
0 replies